AR113224A1 - ANTIBODY CONJUGATES INCLUDING A STING AGONIST - Google Patents

ANTIBODY CONJUGATES INCLUDING A STING AGONIST

Info

Publication number
AR113224A1
AR113224A1 ARP180101063A ARP180101063A AR113224A1 AR 113224 A1 AR113224 A1 AR 113224A1 AR P180101063 A ARP180101063 A AR P180101063A AR P180101063 A ARP180101063 A AR P180101063A AR 113224 A1 AR113224 A1 AR 113224A1
Authority
AR
Argentina
Prior art keywords
antibody conjugates
sting agonist
conjugates including
immunoconjugates
methods
Prior art date
Application number
ARP180101063A
Other languages
Spanish (es)
Inventor
Yongqin Wan
Tom Yao Wu
- Uno Tetsuo Hsiang
George Scott Tria
Leonard Sung
Weijia Ou
Chudiobioma Ndubaku
Sarah Mwhirter
Jeffrey Mkenna
Justin Leong
Thanh Ngoc Lan Le
George Edwin Katibah
Shailaja Kasibhatla
David Kanne
Xueshi Hao
Laura Glickman
Kelsey Gauthier
Thomas W Dubensky
Charles Y Cho
Stephen Canham
Jacob Robert Bruml
Original Assignee
Novartis Ag
Aduro Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Aduro Biotech Inc filed Critical Novartis Ag
Publication of AR113224A1 publication Critical patent/AR113224A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin

Abstract

Se proporcionan en la presente inmunoconjugados que comprenden agonistas de STING. También se dan a conocer métodos para producir los inmunoconjugados y métodos de tratamiento del cáncer usando los inmunoconjugados.Immunoconjugates comprising STING agonists are provided herein. Methods for producing the immunoconjugates and methods of treating cancer using the immunoconjugates are also disclosed.

ARP180101063A 2017-04-28 2018-04-25 ANTIBODY CONJUGATES INCLUDING A STING AGONIST AR113224A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762491879P 2017-04-28 2017-04-28

Publications (1)

Publication Number Publication Date
AR113224A1 true AR113224A1 (en) 2020-02-19

Family

ID=62165655

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101063A AR113224A1 (en) 2017-04-28 2018-04-25 ANTIBODY CONJUGATES INCLUDING A STING AGONIST

Country Status (5)

Country Link
EP (1) EP3615080A1 (en)
JP (1) JP2020517700A (en)
CN (1) CN110799218A (en)
AR (1) AR113224A1 (en)
WO (1) WO2018200812A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170192A1 (en) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co Cyclic dinucleotide
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
PE20210156A1 (en) 2017-11-10 2021-01-26 Takeda Pharmaceuticals Co STING MODULATING COMPOUNDS AND METHODS OF PREPARATION AND USE
EP3505188A1 (en) * 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
AU2019266406A1 (en) 2018-05-09 2020-11-26 Legochem Biosciences, Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
US20210205348A1 (en) * 2018-06-01 2021-07-08 Eisai R&D Management Co., Ltd. Methods for the Treatment of Bladder Cancer
JP7440504B2 (en) 2018-07-10 2024-02-28 エフ－スター・セラピューティクス・インコーポレイテッド Compounds, compositions and methods for treating diseases
WO2020089815A1 (en) * 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
JP2022509929A (en) * 2018-10-31 2022-01-25 ノバルティス アーゲー DC-SIGN antibody conjugate containing STING agonist
PE20211296A1 (en) * 2018-12-21 2021-07-20 Novartis Ag ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF
EP3962493A2 (en) * 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2022531899A (en) 2019-05-09 2022-07-12 アリゴス セラピューティクス インコーポレイテッド Modified cyclic dinucleoside compound as a STING modulator
KR20220006519A (en) 2019-05-10 2022-01-17 다케다 야쿠힌 고교 가부시키가이샤 antibody drug conjugate
AU2020279979A1 (en) 2019-05-20 2021-11-25 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
TW202116358A (en) 2019-07-19 2021-05-01 美商免疫感應治療公司 Antibody-sting agonist conjugates and their use in immunotherapy
CA3149482A1 (en) 2019-08-02 2021-02-11 Mersana Therapeutics, Inc. Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
EP4017593A1 (en) * 2019-08-21 2022-06-29 The Scripps Research Institute Bicyclic agonists of stimulator of interferon genes sting
KR20210028544A (en) * 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 Antibody-drug conjugate comprising antibody binding to antibody against human ROR1 and its use
WO2021046426A1 (en) * 2019-09-06 2021-03-11 Sperovie Biosciences, Inc. Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies
MX2022007798A (en) * 2019-12-23 2022-07-19 Eisai R&D Man Co Ltd Method for producing eribulin-based antibody-drug conjugate.
MX2022009597A (en) * 2020-03-06 2022-09-02 Daiichi Sankyo Co Ltd Antibody-drug conjugate including novel cyclic dinucleotide derivative.
KR20230005189A (en) * 2020-04-02 2023-01-09 메르사나 테라퓨틱스, 인코포레이티드 Antibody Drug Conjugates Containing a STING Agonist
KR20220167275A (en) 2020-04-10 2022-12-20 오노 야꾸힝 고교 가부시키가이샤 cancer treatment methods
US20230149560A1 (en) 2020-04-20 2023-05-18 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
KR20230011324A (en) 2020-05-15 2023-01-20 이뮨센서 테라퓨틱스, 인코포레이티드 Combination therapy with STING agonists using immune checkpoint inhibitors
CN111592570B (en) * 2020-05-15 2022-04-29 清华大学 Novel STING agonists, methods of preparation and uses thereof
PE20231947A1 (en) 2020-11-09 2023-12-05 Takeda Pharmaceuticals Co ANTIBODY AND DRUG CONJUGATES
CA3215049A1 (en) 2021-04-10 2022-10-13 Baiteng ZHAO Folr1 binding agents, conjugates thereof and methods of using the same
JP2024514707A (en) 2021-04-20 2024-04-02 アンスティテュ・クリー Compositions and methods for use in immunotherapy
CN117203238A (en) 2021-04-23 2023-12-08 普方生物制药美国公司 CD70 binding agents, conjugates thereof, and methods of use thereof
TW202320857A (en) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 Linkers, drug linkers and conjugates thereof and methods of using the same
AU2022315305A1 (en) 2021-07-23 2024-02-01 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with cytokines
TW202342105A (en) * 2021-12-17 2023-11-01 大陸商北京加科思新藥研發有限公司 Compound-linker constructs comprising novel compounds useful as sting agonists and uses thereof
WO2024020164A2 (en) 2022-07-21 2024-01-25 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673901B2 (en) 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
DK2281006T3 (en) 2008-04-30 2017-11-06 Immunogen Inc CROSS-BONDING AGENTS AND APPLICATIONS THEREOF
CA2888445A1 (en) 2012-11-30 2014-06-05 Novartis Ag Methods for making conjugates from disulfide-containing proteins
SG11201502796RA (en) 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
SI2953976T1 (en) 2013-02-08 2021-08-31 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
PE20160167A1 (en) 2013-04-29 2016-04-21 Sloan Kettering Inst Cancer COMPOSITIONS AND METHODS TO ALTER THE SIGNALING OF THE SECOND MESSENGER
US9724408B2 (en) * 2013-05-18 2017-08-08 Aduro Biotech, Inc. Compositions and methods for activating stimulator of interferon gene-dependent signalling
US10092644B2 (en) 2013-11-22 2018-10-09 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
SG11201609021QA (en) 2014-06-04 2016-11-29 Glaxosmithkline Ip Dev Ltd Cyclic di-nucleotides as modulators of sting
EP3546473A1 (en) 2014-12-16 2019-10-02 Kayla Therapeutics Cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
CN107530415A (en) * 2015-03-10 2018-01-02 艾杜罗生物科技公司 For activating the composition and method of the conduction of " interferon gene stimulant " dependent signals
US20180117171A1 (en) * 2015-04-01 2018-05-03 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
AU2016287580A1 (en) 2015-07-02 2018-02-15 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of viral infection
TW201717968A (en) 2015-07-14 2017-06-01 春季銀行製藥公司 Compounds and compositions that induce RIG-I and other pattern recognition receptors
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
KR102271750B1 (en) 2015-08-13 2021-06-30 머크 샤프 앤드 돔 코포레이션 Cyclic di-nucleotide compounds as sting agonists
DE212016000029U1 (en) * 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Compositions of antibody construct agonist conjugates
CN106540256A (en) * 2016-03-27 2017-03-29 聊城市奥润生物医药科技有限公司 Ring dinucleotide-application of the liposome conjugated monoclonal antibodies in antitumor
WO2018009652A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
US11033569B2 (en) 2016-07-06 2021-06-15 Sperovie Biosciences, Inc. Compounds,Compositions, and methods for the treatment of disease
WO2018013887A1 (en) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
CN109715202A (en) 2016-07-15 2019-05-03 斯必乐维生物科学公司 For treating the compound, composition and method of disease

Also Published As

Publication number Publication date
EP3615080A1 (en) 2020-03-04
JP2020517700A (en) 2020-06-18
WO2018200812A1 (en) 2018-11-01
CN110799218A (en) 2020-02-14

Similar Documents

Publication Publication Date Title
AR113224A1 (en) ANTIBODY CONJUGATES INCLUDING A STING AGONIST
ECSP18038868A (en) ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
CL2018003406A1 (en) Glucocorticoid receptor agonist and immunoconjugates thereof.
CO2017010618A2 (en) Antibodies against icos
CL2018003758A1 (en) Anti-dll3-antibody antibody conjugates and methods of use. (divisional application 201800458)
CY1124131T1 (en) ANTI-RTK7 ANTIBODY-DRUG CONJUGATS
ECSP19072235A (en) Anti-ILT4 antibodies and antigen-binding fragments
AR111651A1 (en) CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
CR20180243A (en) PIRROLOBENZODIAZEPIN ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
CO2017004782A2 (en) Antibody-drug conjugates
CR20170131A (en) ANTI-HER2 AND IMMUNOCUSED ANTIBODIES
CR20150482A (en) ANTI-B7-H4 ANTIBODIES AND IMMUNOCATION
CR20160257A (en) ANTI-CD33 ANTIBODIES AND IMMUNOCATION
CL2016002667A1 (en) Novel anti-rnf43 antibodies and methods for use
CR20160500A (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
NI201700016A (en) DRUG CONJUGATES WITH ANTI-CDH6 ANTIBODIES
CY1124230T1 (en) Glucocorticoid receptor agonist and immunoconjugates thereof
CL2018001722A1 (en) New anti-mfi2 antibodies and methods of use (divisional application 201700506)
UY38433A (en) DC – SIGN ANTIBODY CONJUGATES INCLUDING STING AGONISTS
BR112017026027A2 (en) anti-cd37 immunoconjugate and anti-cd20 antibody combinations
BR112015027309A2 (en) antibody, composition, method of treatment and use of an antibody
CO2018005393A2 (en) Anti-htra1 antibodies and methods of use thereof
CL2018002050A1 (en) Antibody-drug conjugates directed to gcc.
CO2022009696A2 (en) Anti-lilrb1 antibody and uses thereof
CL2021001593A1 (en) Tubulisins and protein-tubulisin conjugates

Legal Events

Date Code Title Description
FB Suspension of granting procedure